Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting by Hans Kristian Råket, Mikkel Zöllner Ankarfeldt, Joanna Nan Wang, Tacjana Pressler, Søren Jensen-Fangel, Tavs Qvist, Daniel Faurholt-Jepsen, Espen Jimenez-Solem, Janne Petersen, Camilla Bjørn Jensen, on behalf of the TransformCF Study Group

Get full text